Open an account

INmune Bio

INMB · NASDAQ

$1.60+$0.06 (+3.90%)TodayMarket closed ·
Prev close $1.54

About INMB

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 21 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Employees
21
Headquarters
Boca Raton, Florida
Listed
Feb 4, 2019
Sector
Health Care
Industry
Biotechnology
Website
inmunebio.com

INMB key statistics

Market cap
44.41M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
312.20K
Volume
75.61K
Open price
$1.53
High today
$1.63
Low today
$1.53
52 Week high
$2.60
52 Week low
$1.09

INmune Bio (INMB) at a glance

As of Oct 20, 2026, INmune Bio (INMB) shares are priced at $1.60, giving the company a market cap of 44.41M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.53 and $1.63. The current price is 4.6% above the day's low and 1.8% below its high.

Volume so far is 75.61K shares, below the average of 312.20K shares a day.

Over the past year INmune Bio has ranged from $1.09 to $2.60, and now sits 34% of the way up that range.

INmune Bio met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.2108.

The average analyst price target is $8.16, 410.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $8.16
Low
$7.07
Now
$1.60
High
$9.45

INMB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 29.5% on average.

  1. Q3 FY24: reported -$0.60 per share against an estimate of -$0.5066
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.5508
  3. Q1 FY25: reported -$0.43 per share against an estimate of -$0.4794
  4. Q2 FY25: reported -$1.05 per share against an estimate of -$0.3893
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.3315
  6. Q4 FY25: reported -$0.20 per share against an estimate of -$0.2652
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.2244
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.2108

INMB news

  • Press releasePRNewswire

    INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

  • Press releasePRNewswire

    Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

  • Press releaseBusiness Wire

    Biotech Leaders Launch National Alliance to Define the Future of American Innovation

  • Press releaseGlobe Newswire

    INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Mohd Haider

    INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?

  • Vishaal Sanjay

    'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

  • Vishaal Sanjay

    'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Similar companies

Companies in the same industry as INmune Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.